A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type

Clinical Therapeutics

Volumn 32, Issue 11, 2010, Pages 1871-1888

  Nikfar, Shekoufeh ^a,b   Rahimi, Roja ^a,c   Abdollahi, Mohammad ^a,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Efficacy; Interferon ; Meta analysis; Multiple sclerosis; Systematic review; Tolerability

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATALITY; FLU LIKE SYNDROME; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; META ANALYSIS; MULTIPLE SCLEROSIS; MYALGIA; REMISSION; REVIEW; SIDE EFFECT; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 78649380836     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.006     Document Type: Review

References (28)

1. DeAngelis T, Lublin F Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies. Mt Sinai J Med. 2008, 75:157-167.
2. Myhr KM Diagnosis and treatment of multiple sclerosis. Acta Neurol Scand Suppl. 2008, 188:12-21.
3. Alonso A, Hernán MA Temporal trends in the incidence of multiple sclerosis: A systematic review. Neurology. 2008, 71:129-135.
4. Vosoughi R, Freedman MS Therapy of MS. Clin Neurol Neurosurg. 2010, 112:365-385.
5. Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler. 2003, 9:349-355.
6. Nikfar S, Rahimi R, Rezaie A, Abdollahi M A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch Med Sci. 2010, 6:236-244.
7. Martinelli Boneschi F, Rovaris M, Capra R, Comi G Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005, (4):CD002127.
8. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007, 6:975-990.
9. Tyring SK Interferons: Biochemistry and mechanisms of action. AmJ Obstet Gynecol. 1995, 172:1350-1353.
10. Meyer O Interferons and autoimmune disorders. Joint Bone Spine. 2009, 76:464-473.
11. Panitch H, Miller A, Paty D, Weinshenker B Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology. 2004, 63:1788-1795. North American Study Group on Interferon beta-1b in Secondary Progressive MS.
12. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis[published correction appears in Lancet. 1999;353:678]. Lancet. 1998, 352:1498-1504. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
13. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology. 1993, 43:655-661. IFNB Multiple Sclerosis Study Group.
14. Andersen O, Elovaara I, Färkkilä M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004, 75:706-710.
15. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998, 352:1491-1497. European Study Group on interferon beta-1b in secondary progressive MS.
16. Stübgen JP Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 2009, 212:132-141.
17. Jadad A Randomised Controlled Trials 1998, BMJ Books, London, UK.
18. Patti F, L'Episcopo MR, Cataldi ML, Reggio A Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study. Acta Neurol Scand. 1999, 100:283-289.
19. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 2001, 56:1496-1504. Secondary Progressive Efficacy Clinical Trial of Recom- binant Interferon-Beta-1a in MS (SPECTRIMS) Study Group.
20. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology. 2003, 60:44-51.
21. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published correction appears in Ann Neurol. 1996; 40:480]. Ann Neurol. 1996, 39:285-294. Multiple Sclerosis Collaborative Research Group (MSCRG).
22. Fan X, Yang L A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis [in Chinese]. Zhonghua Yi Xue Za Zhi. 2009, 89:1484-1489.
23. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996, 46:907-911. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
24. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b vs once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002, 359:1453-1460. Independent Comparison of Interferon (INCOMIN) Trial Study Group.
25. Nikfar S, Rahimi R, Abdollahi M A systematic review on the efficacy of interferon beta in relapsing remitting multiple sclerosis; comparison of different formulations. Int J Pharmacol. 2010, 6:638-664.
26. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: A systematic review. Lancet. 2003, 361:545-552.
27. Naldini A, Fleischmann WR In vivo myelosuppression by combination interferon treatment: Antagonism of MuIFN-gamma and MuIFN- beta myelosuppressive effects. J Biol Response Mod. 1987, 6:546-555.
28. Tremlett H, Oger J Hepatic injury, liver monitoring and the betainterferons for multiple sclerosis. J Neurol. 2004, 251:1297-1303.